Background Botulinum toxin type A (BoNT-A) has been increasingly investigated for persistent myogenic temporomandibular disorders (TMDs), particularly when conservative therapies provide insufficient symptom control. However, variability in patient selection, injection protocols, outcomes, and safety reporting complica...
Marines Vega Sanchez, Luis Chauca-Bajaña, Francisco Córdova et al.· Journal of Oral Biology and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.